Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login


The Cancer Letter Inc.
PO Box 9905
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Feb 1, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Analysis Evaluates Moore Criteria for Bevacizumab Effectiveness in Cervical Cancer


An analysis of a previously published phase III study prospectively validated five prognostic factors, referred to as the Moore criteria, used to identify a subset of patients with advanced cervical cancer that may not benefit from bevacizumab treatment.

The Moore criteria are five clinical factors that were developed in 2010 to be prognostic for poor outcomes among patients with advanced cervical cancer, and include: being of African-American ancestry and having a performance status of 1, pelvic disease, prior platinum-based treatment, and progression-free survival of less than one year. Patients who have zero or one negative prognostic factor are proposed to be at the lowest risk for poor outcome, those with two or three at intermediate risk, and those with four or five at high risk.

To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.